chrisvoncsefalvay/vaers-outcomes huggingface dataset:
rapid heart beat; shortness of breath; This spontaneous case was reported by a consumer and describes the occurrence of HEART RATE INCREASED (rapid heart beat) and DYSPNOEA (shortness of breath) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.   On an unknown date, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced HEART RATE INCREASED (rapid heart beat) and DYSPNOEA (shortness of breath). At the time of the report, HEART RATE INCREASED (rapid heart beat) and DYSPNOEA (shortness of breath) had not resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, Heart rate: high (High) high.         No concomitant medication were provided by the reporter  No treatment medication were provided by the reporter   Reporter did not allow further contact
Beginning on 12/4/2021, experienced pain at the injection side, moderate headache, nausea, lightheadedness,  lethargy, joint pain in hips, neck, lower back, swollen and painful lymph nodes in left underarm, skin sensitivity, muscle pain in arms and shoulders.  All of these side effects resolved after five days except muscle pain in arms and shoulders.
sick to stomach; diarrhea; no energy; muscle ache; headache; face swell up; turn red; This spontaneous case was reported by a consumer and describes the occurrence of SWELLING FACE (face swell up), ERYTHEMA (turn red), ABDOMINAL DISCOMFORT (sick to stomach), DIARRHOEA (diarrhea) and ASTHENIA (no energy) in a 30-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 012H21B, 039k20A and 004MZ0A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.   On 30-Dec-2020, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 27-Jan-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 19-Jan-2022, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 23-Jan-2022, the patient experienced SWELLING FACE (face swell up) and ERYTHEMA (turn red). On an unknown date, the patient experienced ABDOMINAL DISCOMFORT (sick to stomach), DIARRHOEA (diarrhea), ASTHENIA (no energy), MYALGIA (muscle ache) and HEADACHE (headache). The patient was treated with DIPHENHYDRAMINE HYDROCHLORIDE (BENADRYL [DIPHENHYDRAMINE HYDROCHLORIDE]) for Swelling, at an unspecified dose and frequency and PARACETAMOL (TYLENOL [PARACETAMOL]) at an unspecified dose and frequency. At the time of the report, SWELLING FACE (face swell up) had resolved, ERYTHEMA (turn red) outcome was unknown and ABDOMINAL DISCOMFORT (sick to stomach), DIARRHOEA (diarrhea), ASTHENIA (no energy), MYALGIA (muscle ache) and HEADACHE (headache) had not resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, SARS-CoV-2 test: negative (Negative) Negative.         Patient took steroid shot for treating symptoms. He takes daily medications but did not provided the names and screened Covid since and has come back negative. Concomitant medications was not reported.   Reporter did not allow further contact
Approximately 2min after injection patient slumped down in chair and fainted. She came too briefly then fainted again with snoring resperations. I immediately placed her on the floor and opened airway. I got more help and elevated her feet. Patient came too. Her face was flushed but no other rash on body. No signs of difficulty breathing or cramping. Vitals were b/p of 92/60 with pulse of 88. I placed an ice pack behind her neck and gave her something to drink I monitored her for about an hour. She was able to sit in a seat with no dizziness or difficulty and b/p came up to 96/72. Patient ended up walking out with dad feeling better.
Myocarditis: presenting with body ache, left sided chest discomfort. Moderna vaccine #2 6/4/21.
Worst Migraine headache; Rash; This spontaneous case was reported by a patient and describes the occurrence of MIGRAINE (Migraine Headache) and RASH (Rash) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. Unknown) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) at an unspecified dose. On an unknown date, the patient experienced MIGRAINE (Migraine Headache) and RASH (Rash). At the time of the report, MIGRAINE (Migraine Headache) and RASH (Rash) outcome was unknown.            Reporter did not allow further contact
Severe vomiting during overnight period into next day (approximately 12 episodes in 12 hours), severe cranial pain/headache, open sore in esophagus/lower throat that prevented eating solid foods for 10 days and liquids for at least the first week, even water.  Painful area surrounding sternum (uncertain if it was from the vomiting action or possibly heart damage), which also prevented food or liquid to pass down the throat due to spasms, localized pain and possibility of inducing vomit reflex.   High blood glucose (ketoacidosis).  General overall weakness/lack of energy.  Loss of mucous in nose, throat and stomach.  Loss of saliva in mouth for first week.  Insomnia. High blood pressure.
This is a spontaneous report from a contactable physician reported for her son. A 18-year-old male patient received the first dose of TRUMENBA on 16Dec2015 14:03 at 0.5ml single dose, via intramuscular route on left arm. Medical history included asthma, ongoing and attention deficit/hyperactivity disorder ongoing. Concomitant medication included VIVACE, 60 mg, daily. On 16Dec2015 the patient experienced chills, fever, very bad body aches, couldn't move arm extending to clavicle, felt weakness in both arms, worse in the arm where the injections were given. The outcome of the event couldn't move arm extending to clavicle/couldn't lift his arms was recovered on 20Dec2015, of the event very bad body aches was recovered on 18Dec2015, of the events fever and chills was recovered on 17Dec2015. The outcome of the other events was unknown. The events were considered as not serious. Follow-up (07OCT2016): Follow-up attempts are completed. No further information is expected.
This spontaneous report was received from a medical assistant and refers to a patient of unknown age and gender. No information regarding the patient's pertinent medical history, concomitant medications, drug reactions or allergies was provided. On 15-DEC-2017, the patient was vaccinated with an improperly stored dose of M-M-R II lot # N009800; expiry date 24-MAR-2019 (dose, frequency, route of administration were not provided). The M-M-R II was reconstituted with properly stored dose of sterile diluent (manufacturer unknown). No adverse effect was reported. The vaccines was stored in between 47 degrees Fahrenheit (F) to 77 F (also reported as: "46.9 F") for 30 minutes. There was no previous excursion. The digital data logger was involved in recording the temperature excursion. Sender's Comments: US-009507513-1801USA002561: US-009507513-1801USA002562: US-009507513-1801USA002563: US-009507513-1801USA002564: US-009507513-1801USA002559: US-009507513-1801USA002560.
pt recv vax 19MAR96 & pt was exposed to a child w/chickenpox;27DEC96 pt was feverish & fussy;29DEC96 pt devel a mild breakthrough rash consisting of 40-50 lesions;it was reported that the pt was not particularly ill other than spots;
1 st dose was given on 09Nov2022 and the 2nd dose was given on 28Nov2022; No adverse event; This spontaneous case was reported by an other health care professional and describes the occurrence of INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (1 st dose was given on 09Nov2022 and the 2nd dose was given on 28Nov2022) and NO ADVERSE EVENT (No adverse event) in a child patient of an unknown gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 prophylaxis.     No Medical History information was reported.    On 28-Nov-2022, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 28-Nov-2022, the patient experienced INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (1 st dose was given on 09Nov2022 and the 2nd dose was given on 28Nov2022) and NO ADVERSE EVENT (No adverse event). At the time of the report, INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (1 st dose was given on 09Nov2022 and the 2nd dose was given on 28Nov2022) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessment was provided for INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (1 st dose was given on 09Nov2022 and the 2nd dose was given on 28Nov2022).    Concomitant medications were not reported.                                       No treatment information was provided by the reporter.
Had J&J vax in April. Had Moderna booster on 10/29.  Have a large bruise : rash in an oval shape around armpit under left arm that developed around 24 - 36 hours after shot. It is probably  8 inches long and 4 inches wide. Almost looks like the bulls eye thing you see on people after they get bitten by a tick with Lymes disease.
pt says her right arm was sore the day after taking the vax.  the next day the right arm is painful, hot, red and raised around the injection site about the size of a half dollar.  Pt called PCP and she was instructed to call us.
Arthralgia, injection site arm pain to the point of unable to lift arm for 12-24 hours Narrative:
Bump at injection site - difficulty breathing - vomiting. Given Epi-OK after about 15 min.
08/16/2021-I was having a lot of pain in my breast, my right breast on this morning has a lot of discharge, and it turned to blood. Also, back part of my eye it hurts a lot and a lot of headaches. All these things have continued as of today.
Systemic: Flushed / Sweating-Severe, Systemic: Hypotension-Severe, Systemic: Seizure-Severe, Additional Details: Patient expressed that he didn't like needles. Patient stated that he has gotten flu shots in the past. Immediately after administering the vaccine, patient stopped responding, his eyes bulged, and his arms tensed and both arms went up to his chest. I was calling his name and asking if he was doing okay, he kept staring straight ahead and wasn't responding. Patient eventually came to after a minute. Measured blood pressure twice &, average ~90/55. Offered patient ambulance, patient declined.
The patient received a dose of the vaccine following temperature excursions on unknown dates; No adverse event; This spontaneous report as received from a medical assistant refers to a current 6-month-old patient of unknown gender.  The patient's concurrent conditions, medical history and concomitant medications were not provided.   On an unknown date, the rotavirus vaccine, live, oral, pentavalent (ROTATEQ)  (lot # S013439 with expiration date 03-MAR-2021, lot # S013436 with expiration date 30-JAN-2021, and lot # S006050 with expiration date 12-DEC-2020) underwent a temperature excursion.   Temperature Total Time and LOWEST Temperature BELOW 36°F/2°C (0C) Time frame 7 hours 30 minutes Previous temperature excursion? yes, Total Time and LOWEST Temperature BELOW 36°F/2°C (0C) for 8 hours 30 minutes Was call because of a "data logger"? yes  On an unknown date, the patient was vaccinated with rotavirus vaccine, live, oral, pentavalent (ROTATEQ) at a dose of 2 ml (route not provided) as prophylaxis. No adverse events were reported.  This is one of several reports received from the same reporter  This spontaneous report as received from a other health professional refers to a patient of unknown age.    On an unknown date the patient was vaccinated with rotavirus vaccine, live, oral, pentavalent (ROTATEQ) lot # S006050, 2 milliliter for prophylaxis.       On an unknown date the patient experienced product storage error and no adverse event.    The outcome of product storage error and no adverse event is unknown.   The reporter considered product storage error and no adverse event to be not assessed to Rotavirus Vaccine, Live, Oral, Pentavalent(ROTATEQ).     {Additional information has been requested. / Additional information is not expected.}; Sender's Comments:  US-009507513-2005USA003382: US-009507513-2005USA004545: US-009507513-2005USA004950: US-009507513-2005USA004951: US-009507513-2005USA004952: US-009507513-2005USA004953: US-009507513-2005USA004954: US-009507513-2005USA004955: US-009507513-2005USA004956: US-009507513-2005USA004957: US-009507513-2005USA004958: US-009507513-2005USA004959: US-009507513-2005USA004960: US-009507513-2005USA004961: US-009507513-2005USA004962: US-009507513-2005USA004963: US-009507513-2005USA004964: US-009507513-2005USA004965: US-009507513-2005USA004966: US-009507513-2005USA004967: US-009507513-2005USA004968: US-009507513-2005USA004969: US-009507513-2005USA004970: US-009507513-2005USA004971: US-009507513-2005USA004973: US-009507513-2005USA004974: US-009507513-2005USA004975: US-009507513-2005USA004976: US-009507513-2005USA004977: US-009507513-2005USA004978: US-009507513-2005USA004979: US-009507513-2005USA004980: US-009507513-2005USA004981: US-009507513-2005USA004982: US-009507513-2005USA004983: US-009507513-2005USA004984: US-009507513-2005USA004985: US-009507513-2005USA004986: US-009507513-2005USA004987: US-009507513-2005USA004988: US-009507513-2005USA004989: US-009507513-2005USA004990: US-009507513-2005USA004991: US-009507513-2005USA004992: US-009507513-2005USA004993:
Congestion; Respiratory issues; Oxygen breathing is off; Sweats; Coughing; Fever 100 point something; Really tired; Nausea; This spontaneous case was reported by a consumer and describes the occurrence of PULMONARY CONGESTION (Congestion) in a 76-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     The patient's past medical history included Double vessel bypass graft.   On 17-Mar-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. In March 2021, the patient experienced PULMONARY CONGESTION (Congestion) (seriousness criterion medically significant), RESPIRATORY DISORDER (Respiratory issues), DYSPNOEA (Oxygen breathing is off), HYPERHIDROSIS (Sweats), COUGH (Coughing), PYREXIA (Fever 100 point something), FATIGUE (Really tired) and NAUSEA (Nausea). At the time of the report, PULMONARY CONGESTION (Congestion), RESPIRATORY DISORDER (Respiratory issues), DYSPNOEA (Oxygen breathing is off), HYPERHIDROSIS (Sweats), COUGH (Coughing), PYREXIA (Fever 100 point something), FATIGUE (Really tired) and NAUSEA (Nausea) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): In March 2021, Body temperature: 100 point (Inconclusive) 100 point. In March 2021, Respiratory rate: 92-96-97 (Inconclusive) 92-96-97.         Concomitant product use was not provided by the reporter.  Treatment information was unknown.  Very limited information regarding these events has been provided at this time.  Further information has been requested.; Sender's Comments: Very limited information regarding these events has been provided at this time.  Further information has been requested.
I got a shingles rash, when I got a shot to avoid shingle rash/ suspected vaccination failure; I got a shingles rash, when I got a shot to avoid shingle rash; This case was reported by a consumer via interactive digital media and described the occurrence of suspected vaccination failure in a adult patient who received Herpes zoster (Shingrix) for prophylaxis.   Co-suspect products included Herpes zoster (Shingrix) for prophylaxis.   On an unknown date, the patient received Shingrix and Shingrix. On an unknown date, unknown after receiving Shingrix and Shingrix, the patient experienced vaccination failure (serious criteria GSK medically significant) and shingles. On an unknown date, the outcome of the vaccination failure and shingles were unknown.   It was unknown if the reporter considered the vaccination failure and shingles to be related to Shingrix and Shingrix.  Additional details were reported as follows: The age group was not reported, but was selected adult as per vaccine indication. The age at vaccination was not reported. The patient wanted to know why he/she got a shingles rash, when he/she got a shot of Shingrix to avoid a shingles rash. This case was considered as suspected vaccination failure as details regarding completion of primary vaccination schedule, time to onset for target disease and laboratory confirmation were unknown at the time of reporting.
Information has been received from a physician concerning a memo from their corporate office regarding a four year old patient who had received varicella virus vaccine live (Oka/Merck) booster and immediately experienced facial red spots. It was reported that he was administered emergency Benadryl and stabilized. Current patient status was not reported. No product quality complaint was reported. Further information was not available. This is one of three reports from the same source. Additional information has been requested.
severe h/a, chills, lo grade fever-nausea-itching extremities; swelling-itching-burning lt deltoid lasted 1 1/2 days;
She mentions that it feels like she crushed bottle of Motrin/cannot taste anything except medicinal taste; She noticed that her mouth tasted metallic 2 hours after receiving vaccine.; her mouth tastes bitter; This spontaneous case was reported by a consumer and describes the occurrence of DYSGEUSIA (She mentions that it feels like she crushed bottle of Motrin/cannot taste anything except medicinal taste), DYSGEUSIA (She noticed that her mouth tasted metallic 2 hours after receiving vaccine.) and DYSGEUSIA (her mouth tastes bitter) in a 40-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 048B21A) for COVID-19 vaccination.     No medical history was provided by the reporter.    On 24-Apr-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 24-Apr-2021, the patient experienced DYSGEUSIA (She mentions that it feels like she crushed bottle of Motrin/cannot taste anything except medicinal taste), DYSGEUSIA (She noticed that her mouth tasted metallic 2 hours after receiving vaccine.) and DYSGEUSIA (her mouth tastes bitter). At the time of the report, DYSGEUSIA (She mentions that it feels like she crushed bottle of Motrin/cannot taste anything except medicinal taste), DYSGEUSIA (She noticed that her mouth tasted metallic 2 hours after receiving vaccine.) and DYSGEUSIA (her mouth tastes bitter) outcome was unknown. Not Provided          Concomitant medication included birth control pill. Treatment included eating candy and chewing gum.
Patient received second Moderna vaccine on 2/2 On 2/4 arm became red, swollen, warm, tender Staff outlined the redness, will report if it increases Per PCP take Tylenol
Patient received vaccine at 1:51 p.m. At 1:55 p.m. while in observation area, patient stated she felt dizzy and faint. Feet elevated, RRT called, patient remained alert and verbal. VS 87/56-97.9-50-16-99%RA. At 2:00 p.m. RRT responded, patient states she is feeling better. Patient remained in clinic for further observation. Patient given water and crackers.  VS at 2:00 p.m. 106/65-97.9-86-18-100%RA. RRT exited clinic at 2:03 p.m. Patient states she ate today and that this happens when she gets blood drawn and with her previous vaccine. At 2:30 p.m. VS retaken in sitting position 102/59-97.9-60-18-100%RA. At 2:32 p.m. Vs taken in standing position 112/61-97.9-74-18-100%RA. patient with no c/o at this time. patient educated if any adverse reaction occurs to go to ER. Patient left clinic at 2:33 p.m. with no c/o.
approx 3 hrs p/vax pt began to protrude tongue & roll eyes back w/ ?responsiveness x 5-10mins mom noticed seemed warm, took ax t104;
After the shot my arm was sore and i began my headache the next day. The headache progressed and got worse until that Sunday where i learned i had fever of 103.8. Monday i 3/22 i was admitted in The hospital for seven days with a headache body aches and severe next pain that was not better with morphine, low blood pressure and fever that would not go away.  Also had excessive pressure on the brain.
pt. vax'd w/hepatitis B vac 15Aug90. On 16Aug90 developed headache, malaise, fatigue & tinnitus.
This initial spontaneous report was received from a lawyer regarding a case in litigation and refers to a patient of unknown age and gender. No information was provided regarding concomitant medications, concurrent conditions or medical history. In October 2009, the patient was inoculated with ZOSTAVAX at a pharmacy as recommended for routine adult health maintenance and for the prevention of shingles (lot #, dose and route not provided).  The vaccine did not prevent shingles as intended, and the patient subsequently contracted a persistent strain of herpes zoster.  On or about 01-AUG-2014, the patient was treated at a hospital for a persistent and severe vesicular rash, which was diagnosed as herpes zoster or shingles. As a direct and proximate result of ZOSTAVAX vaccine, and/or despite receiving ZOSTAVAX for long-term prevention of shingles, the patient suffered painful injuries and damages, and required extensive medical care and treatment.  As a further proximate result, the patient has suffered and will continue to suffer significant medical expenses, and pain and suffering, and other damages. The outcome of the events was unknown. Causality assessment was related. Additional information has been requested.
pt received second moderna vaccine 2-8-21; he woke up the morning of 3-8-21, with moderate facial edema. pt denies new meds, foods, hygiene products; not around any new chemicals. denied sob, cough, fever.  he states that he did not have adverse reaction to the 1st vaccine.  (note he did not receive vaccine at our facility)
Appendicitis; This is a spontaneous report from a contactable consumer (patient) reported for herself. A 49-year-old non-pregnant female patient received bnt162b2 (Pfizer-BioNTech COVID-19 Vaccine, solution for injection, (Batch/Lot Number: Unknown)), dose 1 via an unspecified route of administration, administered in right arm on an unspecified date as dose 1, single for COVID-19 immunisation. The patient's medical history included covid prior to vaccination. Concomitant medications included Dispersal sertraline hydrochloride (ZOLOFT), bupropion hydrochloride (WELLBUTRIN), acetylsalicylic acid (ASPIRIN (E.C.)) and gabapentin. Patient had no known allergies. Patient did not receive any other vaccines within 4 weeks to the COVID vaccine. Patient was tested positive prior vaccination and was not tested post vaccination. The patient experienced appendicitis on 02Oct2021. Patient received treatment and visited emergency room for the event. Outcome of appendicitis was recovering.   The lot number for the vaccine, [BNT162B2], was not provided and will be requested during follow-up.